Latest Pluripotency Stories
Pig stem cell research conducted by two animal scientists at the University of Georgia reveals a better way to determine the safety of future stem cell therapies than rodent-based models.
Scientists in Canada have overcome a key research hurdle to developing regenerative treatments for diabetes and liver disease with a technique to produce medically useful amounts of endoderm cells from human pluripotent stem cells.
Tweaking the levels of factors used during the reprogramming of adult cells into induced pluriopotent stem (iPS) cells can greatly affect the quality of the resulting iPS cells, according to Whitehead Institute researchers.
An international study, published today in the prestigious journal Nature Biotechnology, reveals more about human pluripotent stem cells and their genetic stability and has important implications for the development of therapies using these cells.
Human pluripotent stem cells, which can develop into any cell type in the body, rely heavily on glycolysis, or sugar fermentation, to drive their metabolic activities.
In principle, stem cells offer scientists the opportunity to create specific cell types—such as nerve or heart cells—to replace tissues damaged by age or disease.
The possibility that functional, three-dimensional tissues and organs may be derived from pluripotent cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), represents one of the grand challenges of stem cell research, but is also one of the fundamental goals of the emerging field of regenerative medicine.
Inserm's AVENIR "Genomic plasticity and aging" team, directed by Jean-Marc Lemaitre, Inserm researcher at the Functional Genomics Institute (Inserm/CNRS/Université de Montpellier 1 and 2), has recently succeeded in rejuvenating cells from elderly donors (aged over 100).